L. Sparsa

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 291 citations · Full text

Life Sciences, Immunology, Internal Medicine +14

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

Anna Moltó, Clementina López‐Medina, Filip Van den Bosch et al. · Annals of the Rheumatic Diseases · 2021 · 103 citations · Full text

Medicine, Pharmacotherapy, Musculoskeletal Medicine +14

Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis

Ghada Alsaleh, L. Sparsa, Emmanuel Chatelus et al. · Arthritis Research & Therapy · 2010 · 74 citations · Full text

Life Sciences, Immunology, Pathology +16

Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases

Mario Ojeda‐Uribe, Naji Afif, Étienne Dahan et al. · Clinical Rheumatology · 2013 · 71 citations

Life Sciences, Immunology, Obstetrics +14

Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France

Laure Gossec, Athan Baillet, Sabrina Dadoun et al. · Joint Bone Spine · 2016 · 45 citations

Medicine, Health Sciences, Epidemiology +13